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Abstract: Zika virus (ZIKV) infection can cause severe congenital diseases, such as microcephaly,
ocular defects and arthrogryposis in fetuses, and Guillain–Barré syndrome in adults.
Efficacious therapeutic treatments for infected patients, as well as prophylactic treatments to
prevent new infections are needed for combating ZIKV infection. Here, we report that ZIKV-specific
human polyclonal antibodies (SAB-155), elicited in transchromosomal bovine (TcB), provide significant
protection from infection by ZIKV in STAT2 knockout (KO) golden Syrian hamsters both
prophylactically and therapeutically. These antibodies also prevent testicular lesions in this hamster
model. Our data indicate that antibody-mediated immunotherapy is effective in treating ZIKV
infection. Because suitable quantities of highly potent human polyclonal antibodies can be quickly
produced from the TcB system against ZIKV and have demonstrated therapeutic efficacy in a small
animal model, they have the potential as an effective countermeasure against ZIKV infection.
Keywords: STAT2 KO hamster; transchromosomal bovine antibody; Zika virus; therapeutic; testis

1. Introduction
Zika virus (ZIKV) is a mosquito-borne flavivirus in the family Flaviviridae, which not only
affects human adults by causing Guillain–Barré syndrome but also induces microcephaly and death
in congenitally exposed fetuses [1,2]. The recent ZIKV outbreak in South America has resulted in
an unprecedented large number of infection cases [3]. ZIKV has emerged as a public health threat.
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Currently, there are no countermeasures available for the prevention or treatment of ZIKV infection,
except for symptom relief management. Vaccine development is still at its early stages and it is
unknown when an approved ZIKV vaccine will be available.
To address the unmet biomedical needs for the production of therapeutic antibodies,
SAB Biotherapeutics, Inc. has developed a transchromosomic (Tc) bovine platform with the capability
to produce large quantities of fully-human polyclonal antibodies [4]. In this Tc bovine (TcB) system,
bovine immunoglobulin genes were genetically inactivated and the Ig functions were reconstituted by
a human artificial chromosome (HAC) comprising the entire unrearranged human immunoglobulin
repertoire. It has been demonstrated that not only physiological levels of fully-human polyclonal
antibodies can be produced in the blood of TcB but also that TcB can be hyperimmunized with
an antigen of choice to produce highly potent antigen-specific human polyclonal antibodies. Some of
these antibodies have been successfully used to treat a list of viral and bacterial infections [5].
We recently demonstrated that anti-ZIKV human polyclonal antibodies (SAB-155) produced
from TcB administered at −1 and +1 dpi provided 100% protection against ZIKV infection in wild
type mice treated with an anti-interferon receptor antibody and in homozygous Ifnar1 knockout
(Ifnar-/- ) C57BL/6 mice, and eliminated ZIKV induced tissue damages in the brain and testis [6].
In the meantime, as an effort to develop novel animal models of viral infection, we have
developed a signal transducer and activator of transcription 2 (STAT2) gene knockout (KO) golden
Syrian hamster [7]. Compared to the commonly used A129, Ifnar-/- , or the AG129 mice as models of
viral infections, in which either the type I interferon (A129 and Ifnar-/- mice) or both type I and type II
interferon receptors are knocked out (AG129 mice), STAT2 KO hamsters are only partially defective
in type I interferon signaling, thus they are less immunocompromised than the above-mentioned
mouse models. Furthermore, because ZIKV, as well as several other flaviviruses, exerts its infectivity in
humans [8,9] through targeting human STAT2 protein to inactivate human type I interferon responses,
infection of STAT2 KO hamsters by ZIKV would mimic the innate immune responses in humans upon
ZIKV infection. Indeed, we recently have demonstrated that STAT2 KO hamsters are highly susceptible
to ZIKV infection. By using this novel STAT2 KO hamster, the first non-murine rodent model of
viral infection, we recently demonstrated that infection of pregnant hamsters leads to the vertical
transmission of ZIKV to the uterus, placenta, and immune privileged sites, such as the testes and fetal
brain [10].
In the present study, we evaluated the anti-ZIKV human polyclonal antibodies (SAB-155)
produced from TcB both as therapeutic and prophylactic treatments for ZIKV infection in STAT2
KO hamsters. We demonstrated that both treatments with SAB-155 provide significant protection
from lethal infection by ZIKV in the STAT2 KO hamster model. SAB-155 also protected the testes
from ZIKV infection when the animals were treated as late as three days post-infection (dpi).
2. Materials and Methods
2.1. Virus
The ZIKV used in this study was the PRVABC59 ZIKV strain that was originally isolated in Puerto
Rico from the blood of a human patient in December 2015. The virus was provided by Barbara Johnson
(Center for Disease Control and Prevention, Fort Collins, USA). A virus stock was prepared by
two passages in Vero cells and had a titer of 107.5 50% cell culture infectious doses (CCID50 )/mL [10].
2.2. Production of Anti-ZIKV Human Polyclonal Antibodies SAB-155 from Transchromosomal Bovine
The TcB used in this study carries a human artificial chromosome (HAC) comprising the entire
human Ig gene repertoire in the germline genomic configuration in the genetic background
that the endogenous bovine immunoglobulin genes, IGHM; IGHML1; IGL, were sequentially
knocked out (IGHM–/– ; IGHML1–/– ; IGL–/– ) [4]. The generation of anti-ZIKV human polyclonal
antibodies SAB-155 from TcB was described previously [6,11]. Briefly, a plasmid DNA (pDNA)
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encoding a full-length ZIKV prME gene described by Hooper et al. [6] was used as a vaccine to
immunize TcB. The TcB was hyperimmunized 4 times (V1–V4) at 3-week intervals with the antigen
at 12 mg per animal per vaccination by using a PharmaJet Stratis® IM injection device as previously
described [6]. ZIKV-specific antibodies, termed SAB-155, were purified from the plasma collected
from hyperimmunized animals. Negative control antibodies used in this study were human polyclonal
antibodies purified from the sera of the same TcB before ZIKV immunization.
2.3. STAT2 KO Golden Syrian Hamsters
STAT2 KO golden Syrian hamsters produced in-house [7] were used in this study at 5 to 6 weeks of
age. For infection, ~70 pfu of ZIKV was administered to STAT2 KO hamsters by the subcutaneous (s.c.)
route in the inguinal area. For prophylactic and therapeutic treatments, different doses of SAB-155,
in the range of 1 mg to 400 mg/kg were administered via intraperitoneal (i.p.) injections.
2.4. Serum and Tissue Collection
Serum was separated from whole blood using serum separator tubes by centrifugation
at 12.5 × 103 g for 5 min and stored −80 ◦ C before use. Testicular tissues were collected for quantifying
ZIKV RNA, ZIKV-immunohistochemistry (IHC) assays, and histological analysis. For RT-PCR,
tissue was homogenized in Trizol™ in a microcentrifuge with a Teflon pestle, and frozen until
RNA extraction [10,12]. Either the other testis from the same animal or remaining tissue from the same
testis was fixed using freshly prepared 4% paraformaldehyde. Prior publications from our laboratories
and others reiterated that the testis was one of the target organs for ZIKV infection in rodents [13–15]
therefore we used the testis as one of the major organs to evaluate with the TcB antibody. Both sexes
were susceptible for disease leading to a moribund state. Twenty-four hours later the tissues
were rinsed once in PBS and placed in 70% ethanol. Paraffin-embedded tissues were sectioned
at 5 µM thickness and processed for hematoxylin-eosin (HE) staining and ZIKV-immunoreactive
(ZIKV-ir) assays.
2.5. ZIKV Plaque Reduction Neutralization Test (PRNT)
The neutralizing activities of hamster serum antibodies were determined by a plaque reduction
assay [16]. After incubation at 56 ◦ C for 30 min, 2-fold serial dilutions of serum were mixed
and incubated at 4 ◦ C overnight with a stock of ZIKV (100 PFU), with a final starting dilution of
1:10 of each serum sample. A total volume of 200 µl serum with PBS and ZIKV mixture was added to
each well of a twelve-well plate containing Vero 76 cells at 90% confluence. The plate was incubated
for 1 h with periodic rocking at 37 ◦ C. One ml of agarose overlay media was added and incubated
at 37 ◦ C. Three days later, the cells were stained with a crystal violet solution containing formaldehyde
and the plaques were counted. The inverse of the dilution that caused a 50% reduction was reported
as the 50% plaque reduction neutralization titer (PRNT50 ). The titer of the infectious virus was similarly
determined, except that no serum was added to the sample.
2.6. ZIKV RT-PCR
Serum RNA was extracted using QIAamp Viral RNA mini-kit from Qiagen
(Qiagen, Germantown, MD, USA). Fifty to 100 mg of freshly isolated tissue or 0.1 mL of tissue
homogenized with a pestle was added to 900 µL of Trizol Reagent™ (Molecular Research Center,
Cincinnati, OH, USA) for RNA extraction. RNA was suspended in RNAsecure (Life Technologies,
Carlsbad, CA, USA) and was amplified by a quantitative RT-PCR. Ten microliters
of 2 Å~ SensiFASTTM Probe No-ROX One-step Mix, (Bioline, Memphis, TN, USA) with
polymerase and reverse transcriptase, along with Malaysian ZIKV primers (20 µM)
(50 -CTGTGGCATGAACCCAATAG-30 , 30 -ATCCCATAGAGCACCACTCC-50 ) and probe (20 µM)
(50 -FAMCCACGCTCCAGCTGCAAAGG-30 TAMRA) labeled with a FAM fluorophore and TAMRA
quencher (GenScript, Piscataway, NJ, USA), respectively, were mixed with 2 µL of extracted RNA.
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Each sample was run in duplicate and relative genome equivalents were averaged. GAPDH primers
(20 µm) and probe (20 µm) were also included. ZIKV RNA was reverse transcribed for 10 min at 45 ◦ C,
then heated to 95 ◦ C for 2 min. The PCR amplification cycles were 40 cycles at 95 ◦ C for 5 s, and 60 ◦ C
for 20 s. Standard curves of ZIKV RNA and GAPDH RNA were generated with serial dilutions
of synthetic RNA (GenScript, Piscataway, NJ, USA) of the target sequence (accession HQ234499.1)
diluted in normal mouse total RNA (Agilent Technologies, Santa Clara, CA, USA). The thermocycler
was Mic-2 qPCR (Bio Molecular Systems, Taunton, MA, USA). The relative number of ZIKV RNA
was determined from the standard curve and was normalized with relative total RNA calculated from
the GAPDH standard curve. We had previously validated that GAPDH levels were not modified
by ZIKV infection. The limit of detection was calculated based on the titer values from sham or
uninfected testis tissue.
2.7. Immunohistochemistry (IHC) and Histology
Following de-paraffinization, tissue sections were blocked with normal goat serum
for 60 min at room temperature [17]. Either mouse anti-flavivirus group antigen monoclonal
antibody (Millipore, Temecula, CA, USA) or mouse monoclonal antibody to ZIKV NS1 protein
(Aalto Bio Reagents, Dublin, Ireland) was incubated on the tissues for overnight. After a brief
wash with PBS, sections were incubated with a fluorescence-conjugated secondary antibody
(Invitrogen, Grand Island, NY, USA) at room temperature for 2 h. Images were captured using
Zeiss microscope, AxioVision 4.0.1 and processed using Adobe Photoshop. Hematoxylin and eosin
(H&E) staining was performed to study the morphological diagnoses (Table 1) and it was read by
a veterinary anatomic pathologist (Dr. A.V.W).
2.8. Ethics Statement
The experiments were conducted in strict accordance with guidelines of the AAALAC accredited
Laboratory Animal Research Center at Utah State University and approved by the Institutional
Animal Care and Use Committee of Utah State University (IACUC Protocol: 2667; approval date:
27 September 2016).
3. Results
3.1. ZIKV Infection in STAT2 KO Hamsters
To characterize the activity of neutralizing antibodies, the kinetics of viremia and viral presence
in the testis of STAT2 KO hamsters following ZIKV infection, we infected three age-matched
(6 weeks of age) male hamsters via the s.c route with PRVABC69 (~70 pfu) ZIKV. Sera were
collected at 2, 3, and 4.5 dpi for detecting neutralizing antibody titers. Based on the PRNT50
data (Figure 1A), sera assayed at these time-points had detectable levels of ZIKV-specific neutralizing
antibody, indicating that infection can elicit a neutralizing antibody response in STAT2 KO hamsters.
Significant serum viremia was also found at 3 dpi (2/3 animals) and 4.5 dpi (3/3) animals (Figure 1B).
To investigate ZIKV infection in testis, testicles were harvested at 2, 3, and 4.5 dpi for ZIKV
RNA detection and immunohistochemistry analysis. ZIKV RNA levels were significantly higher
in two animals on both the right and left testis at 3 and 4.5 dpi than at 2 dpi (Figure 1C). Parts of
the testicular tissues from the same animals were also analyzed with IHC. ZIKV-ir, while negative
for the testes isolated at 2 dpi, was positive in between the seminiferous tubules at 3 dpi and 4.5 dpi,
possibly from infection of interstitial cells of the testis (Figure 1D–F). This clearly correlated with
the presence of ZIKV RNA (Figure 1C) in the testes and indicated that ZIKV can establish infections in
the testis as early as 3 dpi (but not 2 dpi).
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Figure 1. Defining Zika virus (ZIKV) infection on STAT2 KO hamsters during acute infection.
Serum PRNT (A), ZIKV RNA titers in serum (B) and testes (Ct values) (C), and immunohistochemistry
of ZIKV antigens in testes at 2, 3, and 4 dpi (D–F). Three animals were processed for each time
point (A–C). Tissues from both right and left testes were processed for RT-PCR (C) and representative
IHC images are shown with ZIKV infection (D–F). **, p < 0.005 by one-way ANOVA, sham infection
compared with ZIKV infection. Horizonal dashed lines designate limit of detection in Figure 1A–C
based on sham infection; vertical dashed lines separate infected animals from sham infected ones.
Each of the animals were color-coded in A–C.

3.2. Prophylactic Treatment by SAB-155 of ZIKV Infection in STAT2 KO Hamsters
In order to evaluate the prophylactic efficacy of SAB-155 in protecting STAT2 KO hamsters
from ZIKV infection, equal numbers of age-matched male (n = 6) and female (n = 6)
hamsters (6-weeks of age) were prophylactically treated by a single i.p injection of 100 mg/kg SAB-155
one day prior to ZIKV infection. Sham infected control groups with three hamsters from each sex were
also included. As shown in Figure 2A, all of SAB-155-treated animals survived (except for one that died
from eye bleeding procedures), whereas 42% (5 out of 12) animals in the control-antibody treated group
succumbed. In addition, SAB-155-treated animals did not lose weight while the control-antibody
treated animals started to lose weight at 3 dpi and continued to lose weight through 9 dpi (Figure 2B).
STAT2 KO hamsters exhibited conjunctivitis after ZIKV infection, which was significantly reduced in
animals treated prophylactically with SAB-155: 50% (6 out of 12) of the control-antibody treated animals
were free of conjunctivitis, while 81% (9 out of 11) of SAB-155 treated animals were free of eye disease
(Figure 2C). Furthermore, 100% of the animals with conjunctivitis became moribund in the control
antibody-treated group. Higher titers of ZIKV RNA were detected in the control antibody treated
group than in the SAB-155 treated group (Figure 2D; PRNT data Figure 2E) suggesting prophylactic
administration of SAB-155 at −1 dpi with a single dose of 100 mg/kg can inhibit ZIKV replication
leading to effective prophylactic protection.
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Figure 2. Prophylactic i.p. administration of SAB-155 to ZIKV infected STAT2 KO hamsters.
Equal numbers of male (n = 6) and female (n = 6) s.c. infected with PRVABC69 ZIKV. Sham infected
controls had three each from both sexes. (A) Survival, arrowhead indicates treatment as one day before
viral challenge (−1); (B) daily percent changes in the weights of surviving animals relative to the day
of virus challenge; (C) percent free of eye disease, conjunctivitis; (D) Presence of ZIKV RNA in serum
at 3 dpi. (E) Serum PRNT from serum of animals as in (D). *, p < 0.05; unpaired t-test; ****, p < 0.0001 by
one-way ANOVA compared between SAB-155 vs. negative control antibody treatment. Dashed lines
designate limit of detection in Figure 2D,E.

3.3. Therapeutic Treatment by SAB-155 of ZIKV Infection in STAT2 KO Hamsters and Identifying the Effective
Treatment Time Windows
We subsequently conducted experiments to investigate the efficacy of therapeutic SAB-155
treatments on ZIKV infection and disease and to identify how late after infection an effective treatment
can be administered. Equal numbers of age-matched (6-week) male (n = 4) and female (n = 4)
STAT2 KO hamsters were infected with ZIKV followed by treatment of SAB-155 via the i.p. route
at either −1 dpi (treatment control group), 3 dpi, or 4.5 dpi. Sham infected control groups had two male
and two female hamsters. As shown in Figure 3A, a single dose SAB-155 administered via i.p. injection
at a dose of 100 mg/kg at −1, 3, and 4.5 dpi prevented STAT2 KO hamsters from becoming moribund
(Figure 3A), whereas the negative control antibody treated group started to become moribund at 8 dpi.
Such data indicate that SAB-155 treatment as late as 4.5 dpi is effective in protecting hamsters
from morbidity. It is interesting to note that, judged on a significant (p < 0.002) improvement in
weight change, the therapeutic treatments at 3 and 4.5 dpi provided similar protection as prophylactic
treatment (−1 dpi) (Figure 3B). It is unclear why the hamsters in the sham-infected group treated
with SAB-155 on 1 dpi did not gain weight but we speculate that this was mostly caused by handling
procedures during the experiments that have yet to be identified.
Next, in order to evaluate protective effect of SAB-155 against ZIKV infection in testicular tissues,
RT-PCR and IHC were performed on the testes of surviving animals at the end of the experimental
period on 21 dpi. As shown in Figure 3C, SAB-155 administered at −1 and 3 dpi to STAT2 KO
hamsters resulted in undetectable ZIKV RNA in their testes (Figure 3C). On the contrary, high levels
of ZIKV RNA were detected in the testicular tissues collected on 21 dpi from the surviving male
hamsters that were treated on 4.5 dpi (Figure 3C), even though animals treated at 4.5 dpi did not
display mortality or body weight loss (Figure 3A,B). This suggests that ZIKV can cross blood-testis
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barrier and persistently infect seminiferous tubules and that SAB-155 treatment as late as 4.5 dpi is
ineffective in viral clearance. The histology also showed that one of the four animals treated at 4.5 dpi
had severe pyogranulomatous inflammatory infiltrates (Figure 3H and Table 1). ZIKV-ir indicates
possible infection of interstitial cells, as well as cells lining the seminiferous tubules (Figure 3I’).
The presence of ZIKV RNA (Figure 3C) in the testes corresponds with the histological lesions
(Figure 3D–I) and ZIKV-immunoreactivity (Figure 3D’–I’). None of the STAT2 KO hamsters treated
with SAB-155 at −1 and 3 dpi exhibited any lesions (Figure 3F,G) nor showed ZIKV-immunoreactivity
within the interstitium and seminiferous tubules (Figure 3F’,G’). Such data indicate that SAB-155
treatment as late as 3 dpi provided complete protection against ZIKV infection in the testis. Two out of
four animals treated with SAB-155 on 4.5 dpi had pyogranulomatous inflammation in the interstitium
and seminiferous tubules (Table 1) along with ZIKV positive cells (red color, Figure 3H’) even though
the animal did not lose weight and survived to the end of the experimental period (Figure 3B).
This suggests that STAT2 KO hamsters can be used as a non-lethal animal model to study antivirals
and vaccine treatment against ZIKV infection.
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Figure 3. Identifying effective day of treatment with single dose of 100 mg/kg of SAB-155.
Equal numbers of male (n = 4) and female (n = 4) STAT2 KO hamsters infected with ZIKV PRVABC69
and treated i.p. with SAB-155 at different pre-and post-infection days either at −1, 3 or 4.5 dpi.
Sham infected controls had 2 males and 2 female hamsters. (A) survival, (since five groups had 100%
survival, data has been adjusted to display all groups); (B) temporal change in body weight relative to
the day of virus challenge; (C) RT-PCR analysis of ZIKV RNA in testes of hamsters that survived up
to at 21 dpi compared with sham infection; (D–I), Hematoxylin and eosin staining of cross section of
testis tissue from ZIKV infected and SAB-155 treated STAT2 KO hamsters. Arrows on the H pointing to
the infiltrated cells. (D’–I’) immunohistochemical staining of ZIKV antigen (red color) in cross-section
of testes tissue and DAPI (blue color) stained nuclei. **, p < 0.05; ***, p < 0.001; compared 1 dpi negative
control antibody 100 mg/kg treated group with other groups, using one-way ANOVA test. Dashed lines
indicate limit of detection in Figure 2C.
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3.4. Dose Titration of Therapeutic Treatment with SAB-155 against ZIKV Infection
After demonstrating the efficacy of SAB-155 at a single dose of 100 mg/kg administered on 4.5 dpi
at preventing morbidity, but not testicular infection, we investigated whether a single treatment with
higher doses of SAB-155 could eliminate testicular infection and a lower dose of SAB-155 can still
prevent animals from weight loss. Towards these goals, we tested 200 mg/kg and 400 mg/kg for
the higher doses and 10 mg/kg for the lower dose. Survival (Figure 4A), weight loss (Figure 4B),
percentage of free disease signs (Figure 4C), and RT-PCR on ZIKV RNA (Figure 4D) were evaluated
for all treatment groups. We also performed H&E and IHC analyses on testicular tissues at 21 dpi
for the higher dose groups (Table 1). A dose of 10 mg/kg SAB-155 treatment administered on 4.5 dpi
prevented 88% (7 out of 8) animals from morbidity (Figure 4A). However, significant weight loss
was observed in this low dose group of animals starting at 9 dpi (Figure 4B) and about 80% of
animals showed disease signs (Figure 4C). In comparison, treatments with the higher doses of SAB-155
(200 mg/mL and 400 mg/kg) provided nearly 100% protection from morbidity (Figure 4A), while only
marginally alleviating weight loss and disease signs (Figure 4B and 4C). As shown in Figure 4D,
high levels of ZIKV RNA were still detected at 21 dpi in the testicular tissues of the hamsters treated
at higher doses at 4.5 dpi, even though no mortality was observed. The detection of ZIKV RNA is
consistent with the detection of pathological lesions and positive ZIKV-ir in this organ as summarized
in Table 1. This indicates that at 4.5 dpi, neither of the two tested higher doses can provide complete
protection against ZIKV infection in the testis.
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Figure 4. Identifying effective dose of SAB-155 treatment. Most of the groups had equal numbers of
male (n = 4) and female (n = 4) STAT2 KO hamsters s.c. infected with PRVABC69 and treated with
different doses of SAB-155 at 4.5 dpi and negative control antibody at 1 dpi by i.p. administration.
Groups treated with SAB-155 of 200 and 400 mg/kg had 6 male and 2 female hamsters. Sham infected
controls had 3 each from both sexes. (A) Percent survival, (since three groups had 100% survival,
Y axis was adjusted to display all groups); (B) percent change in body weight relative to the day
of virus challenge; (C) percent free of conjunctivitis; (D) RT-PCR analysis of ZIKV RNA in testis
at 21 dpi. *, p < 0.05 survival curve analysis (A). P-values obtained by comparing negative control
antibody 100 mg/kg with 10 mg/kg of SAB-155 treated at 1 dpi. Dashed lines represent limit of
detection in Figure 3D.
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Table 1. Effect of SAB-155 antibody treatment on testis of Zika virus infected STAT2 KO hamsters.

SAB -155
treatment
Negative
controls

Identifying effective day of
antibody treatment **

Testis
Treatment Day

SAB-155
Antibody Dosage

−1 dpi

ZIKV RNA by
RT-PCR

Morphological Diagnoses *

Immunohistochemistry

Lesions/Total No. of
Male Hamster
Necropsied

100 mg/kg

Below the limit of
detection (<105.5 )

No significant lesions

4/4 No ZIKV infected cells found

0/4

3 dpi

100 mg/kg

Below the limit of
detection (<105.5 )

No significant lesions

4/4 No ZIKV infected cells found

0/4

4.5 dpi

100 mg/kg

106 –1010

Pyogranulomatous inflammatory
exudate infiltrates.

1/4 animal had ZIKV antigen in ST.

1/4

1 dpi

Irrelevant Ab.
100 mg/kg

109

Diffusely pyogranulomatous inflammatory
exudate infiltrates expand and replaces
the interstitium of ST.

2/4 animal had ZIKV antigen in ST.
2/4 animal died before 21 dpi.

2/2

1 dpi

100 mg/kg

Below the limit of
detection (<105.5 )

No significant lesions

No ZIKV infected cells found

0/4

1 dpi

Irrelevant Ab.
100 mg/kg

Below the limit of
detection (<105.5 )

No significant lesions

No ZIKV infected cells found

0/4

4.5 dpi

200 mg/kg

106 –1011

1/6 with a minimal pyogranulomatous
orchitis. 4/6 with a severe
pyogranulomatous orchitis

6/6 animals had ZIKV antigen in ST.

6/6

4.5 dpi

400 mg/kg

105 –108

1/6 with a severe pyogranulomatous orchitis.

6/6 animals had ZIKV antigen in ST.

6/6

5/6

SAB-155
treatment
Negative
controls

Identifying effective dose of
antibody treatment ***

Uninfected controls **

Uninfected Controls ***

4.5 dpi

Irrelevant Ab.
400 mg/kg

106 –1010

5/6 with a severe pyogranulomatous orchitis.

5/6 animals had ZIKV antigen in
ST.1/6 animal had coagulative
necrotic testis. 1/6 animal died
before 21 dpi.

1 dpi

Irrelevant Ab.
100 mg/kg

108

3/4 animal died before necropsy. One animal
survived with severe
pyogranulomatous orchitis.

3/4 animal died before necropsy.
1/4 animal with heavy ZIKV+ve ST.

1/1

1 dpi

100 mg/kg

Below the limit of
detection (<105.5 )

No significant lesions

No ZIKV infected cells found

0/6

1 dpi

Irrelevant Ab.
400 mg/kg

Below the limit of
detection (<105.5 )

No significant lesions

No ZIKV infected cells found

0/6

1 dpi

Vehicle

Below the limit of
detection (<105.5 )

No significant lesions

No ZIKV infected cells found

0/6

*: Hematoxylin and eosin stained slides read by board certified veterinary pathologist. **: One each testis processed for RT-PCR and IHC. ***: same testis tissue processed for RT-PCR and IHC.
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4. Discussion
Several mouse models of ZIKV infection, such as the stat2-/- [18], A129 (Ifnar-/- ), AG129,
triple KO, and WT mice treated with type I IFN-blocking antibody have been
reported with a variety of treatment strategies including small molecule antivirals and antibodies [19].
We recently reported that adult STAT2 KO hamsters are highly susceptible to ZIKV infection
and that ZIKV RNA titers were detected in the testis, kidney, brain and spinal cord of infected
STAT2 KO hamsters [10]. Compared to stat2 KO mice which develop uniform lethal phenotype upon
ZIKV infection, only about 50% of STAT2 KO hamsters infected by ZIKV succumbed (Figure 2A),
with the onset of death being delayed a few days in the hamster than in the mouse [18]. A side by
side comparison between the stat2 KO mouse model and the STAT2 KO hamster model challenged
with same strains of ZIKV would be interesting to investigate the difference between species in
the development of the pathogenesis of ZIKV infection. Since STAT2 KO hamsters often survive
for the duration of the experimental period, i.e., 21 dpi, with viral RNA present in the testis, brain,
and other organs, this unique hamster model provides an opportunity to test the efficacy of prophylactic
and therapeutic treatments with anti-ZIKV antibodies.
Currently, there are no FDA approved ZIKV vaccines or antiviral drugs available, therefore,
there is an urgent need for the development of efficient control strategies for this emerging
pathogen. A number of antivirals have been shown to be active against ZIKV infection in
immunodeficient AG129 [12,20], A129 (Ifnar-/- ) [21], and immunocompetent C57BL/6 mouse
models [22]. Apart from the antivirals, antibodies with inactivated Fc receptors have also been
shown to be protective in both immunocompromised and immunocompetent pregnant rodent
models. Convalescent sera from ZIKV-infected patients [23], monoclonal antibody from DENV
patients [24], and ZIKV-117 mAb from human antisera [25] were tested against different strains of
ZIKV virus in several mouse models. Hundreds of monoclonal antibodies targeting the E protein
of ZIKV with neutralization activity of <1µg/mL, either derived from human patients or mice,
have also been identified [26]. In primate models, the administration of a cocktail of potent neutralizing
monoclonal antibodies collected from ZIKV-infected patients completely prevented serum viremia [27].
In the present study, we used a unique hamster model to investigate the prophylactic and therapeutic
effects of SAB-155 against ZIKV infection. We were particularly focused on the potential of SAB-155 in
eliminating ZIKV in the testis, and to gather some preliminary scientific information on the potential
of using SAB-155 to treat sexual transmission.
We first characterized the kinetics of viremia, the development of neutralizing antibodies,
and the presence of virus in STAT2 KO hamsters following ZIKV infection. We established
that endogenous anti-ZIKV neutralizing antibody responses are elicited by 3 and 4 dpi. Viral RNA
and ZIKV-ir in the testis are also detectable during this time window. We then tested whether a single
dose of SAB-155 administered prophylactically at −1 dpi would be able to protect the hamsters
from morbidity, weight loss, and conjunctivitis. Our results showed that prophylactic treatment
at −1 dpi at a dose of 100mg/kg of SAB-155 was effective in preventing hamster mortality (Figure 2A)
and weight loss (Figure 2B), as well as a reduction in disease signs (conjunctivitis; Figure 2C).
Based on these data, it appears that prophylactic treatment with TcB antibodies can be an effective
countermeasure against ZIKV infection. However, further studies in non-human primate models or in
clinical trials will need to be conducted to test this possibility.
Our study on the kinetics of viremia and the time frame to effectively treat ZIKV infection with
SAB-155 also provided valuable data on when therapeutic intervention could be effective. It is striking
that treatment with a single dose of 100 mg/kg SAB-155 as late as at 4.5 dpi can still fully protect
animals from morbidity, even though these animals had high levels of ZIKV RNA and positive ZIKV-ir
in their testicular tissues on 21 dpi. Furthermore, our data showed that a single therapeutic treatment
with SAB-155 at or before 3 dpi prevented animals from being ZIKV-ir in the testis and developing
histopathological lesions provided the possibility that sexual transmission of ZIKV could be prevented
if the treatments can be administered early enough post infection.
Irf3-/- Irf5-/- Irf7-/-
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In summary, we first demonstrated ZIKV infection and immunotherapy in a new rodent animal
model, the STAT2 KO hamsters. According to the FDA animal efficacy rule, the development of
therapeutic interventions against serious conditions, such as those caused by ZIKV, should be demonstrated
to be efficacious in more than one animal species. Second, we demonstrated that SAB-155 is highly
effective, both prophylactically and therapeutically, in treating ZIKV infection in this hamster model.
In contrast to other animal-derived monoclonal antibodies, SAB-155 is fully-human (non-immunogenic
to patients), polyclonal (recognizing multiple antigens on a virus to effectively reduce or eliminate
viral evasion caused by viral mutations) and can be produced very quickly and in large quantities
(up to 600 g fully human immunoglobulin can be produced per Tc bovineper month; our unpublished
observations). These advantages over other antiviral therapies could potentially make SAB-155, as well
as the TcB platform, a powerful countermeasure in fighting ZIKV infection. It is worth noting that TcB
derived fully human polyclonal antibodies elicited against several other viruses or bacteria have been
shown to be effective to treat infections caused by various infectious pathogens [5,6,11,28–31]. Some of
these TcB antibodies have already been proven to be safe and efficacious in human clinical trials [31,32].
The anti-ZIKV TcB antibodies reported in this study are yet to be tested in rigorous human clinical
trials to be proven effective in treating ZIKV in human infections.
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